SCHEMBL25311559

SCHEMBL25311559

COC(=O)c1ccc(F)c(OCCCc2c(C)n[nH]c2C=O)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 6/20 0.77
▸ ALB P02768 1/20 0.61
▸ AR P10275 1/20 0.45
▸ HSD17B10 Q99714 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ ERN1 O75460 2/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ MAPT P10636 2/20 0.36
▸ NOTUM Q6P988 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ P2RX7 Q99572 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26740141 0.90 TTR (0.64) TTRALBARHSD17B10GAA
SCHEMBL15816962 0.87 TTR (1.00) TTRALBARHSD17B10GAA
SCHEMBL26745347 0.84 TTR (0.79) TTRALBARHSD17B10GAA
SCHEMBL17522791 0.84 TTR (0.94) TTRALBARHSD17B10GAA
SCHEMBL29433285 0.81 TTR (0.72) TTRALBARHSD17B10GAA
SCHEMBL29433284 0.81 TTR (0.72) TTRALBARHSD17B10GAA
SCHEMBL25310955 0.81 TTR (0.72) TTRALBARHSD17B10GAA
SCHEMBL19801746 0.79 TTR (0.84) TTRALBARHSD17B10GAA
SCHEMBL26746919 0.78 TTR (0.48) TTRALBARHSD17B10GAA
SCHEMBL21378627 0.78 TTR (0.81) TTRALBARSMN1; SMN2NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS LTD (GB) 2023-11-09 — — US disclosed
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS LTD (GB) 2023-11-09 — — US disclosed
EP-4214189-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL Business Ltd (GB) 2023-07-26 — — EP disclosed
WO-2022058733-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS PLC (GB) 2022-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS TTR, C1R, APOB TTR 1/4885ALB 6/4885AR 954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback